SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas sharp selloff is being linked by traders to unconfirmed rumors of leaked Phase 3 melanoma-vaccine data and a YouTubers disclosed bearish put position; the community disputes whether either explains the move. Attention also centers on the forthcoming full trial readout, with bulls and bears debating whether expectations have run too high.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp semiconductor selloff, compounded by worries about oil and geopolitical tensions, AI financing, and Lam Researchs supply constraints and China outlook, has driven SOXL discussion. Traders are split between buying the dip and warning that the sectors weakness and the funds 3x leverage could bring further losses.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia shares are selling off despite a third-quarter earnings beat, as traders focus on weaker cash-flow conversion guidance, negative free cash flow and higher restructuring costs. Bulls view the decline as an overreaction to investment in supply and AI-driven growth, while bears question whether strong AI and cloud demand can translate into cash.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

A large scheduled insider-share unlock is the dominant concern as SpaceX gives back its post-earnings gains, with traders citing added selling pressure alongside weakness in the broader tech market. Bulls see the pullback as a buying opportunity after a strong report, while bears warn that further unlocks and Tesla merger uncertainty could weigh on shares.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

A sharp selloff in SNDK and other memory stocks has traders debating whether AI-spending concerns, China competition fears, and weakness in Korean markets point to more downside. Some are buying the pullback ahead of earnings, citing AI-driven NAND demand, while others expect continued selling after repeated failed rebounds.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Metas post-earnings selloff is focused on rising AI infrastructure spending, negative free cash flow and concerns that new nonvoting shares could enable capital raising and dilute shareholders, despite strong advertising results. Traders are divided between viewing the drop as an overreaction and buying the dip, or questioning whether the AI investment can generate returns that justify its cost.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention amid a sharp Nasdaq and tech selloff, with traders focused on concerns about AI spending and funding, alongside Iran-related oil and market risks. The conversation is largely bearish, though some traders see oversold conditions and are looking for a rebound.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is caught in a sharp semiconductor selloff, with traders debating AI infrastructure spending and returns, geopolitical and oil-related macro fears, and weakness in Asian chip stocks. Bulls call the decline a sentiment-driven overshoot and point to strong memory demand, while bears warn that memorys cyclical nature could bring oversupply and further downside.

Forgent Power Solutions, Inc. is a holding company, which engages in the design and manufacture of electrical distribution equipment used in data centers, power grid, and energy-intensive industrial facilities. It also offers powertrain solutions and standard and custom products. The company was founded on July 21, 2025 and is headquartered in Dayton, MN.

Forgent Power Solutions Inc. - Ordinary Shares - Class A

Forgent Power Solutions Inc.

Forgents CFO is stepping down, triggering a sharp selloff as traders debate whether the departure signals undisclosed financial problems or is a personal decision; the company says he will remain as a consultant during the transition. Some investors are calling the drop an overreaction and pointing to the companys growth and backlog, while others want management to provide reassurance.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobes sharp rebound has traders debating whether it reflects an oversold bounce, short covering, or rotation back into beaten-down software rather than a confirmed change in fundamentals. The bullish reaction contrasts with persistent concerns that AI and free open-source clones could pressure Adobes creative-software business, alongside recent analyst downgrades.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced presentations related to its clinical development programs at the European Society for Medical Oncology (ESMO) Congress 2026, taking...

Is CryoPort (CYRX) Outperforming Other Medical Stocks This Year?

Here is how CryoPort, Inc. (CYRX) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.

Teleflex (TFX) Soars 4.4%: Is Further Upside Left in the Stock?

Teleflex (TFX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains?

Veracyte (VCYT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Are Medical Stocks Lagging  Delcath Systems (DCTH) This Year?

Here is how Delcath Systems, Inc. (DCTH) and Encompass Health (EHC) have performed compared to their sector so far this year.

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems, Inc. (Nasdaq: DCTH) (the Company or Delcath), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Companys Compensation Committee, as material...

Zacks.com featured highlights include EuroDry, RCM, Assembly Biosciences, Delcath and National Energy Services

EuroDry, RCM Technologies, Assembly Biosciences, Delcath Systems and National Energy Services show strong price momentum after August's market gains.

Keep Portfolio Volatility in Check With VLO, PBF, FET & DCTH

VLO, PBF, FET and DCTH screen as low-beta picks as volatility rises, backed by refining, energy-equipment and liver-cancer growth drivers.

5 Stocks With Recent Price Strength Buoyed by a Strong August

EDRY, RCMT, ASMB, DCTH and NESR show strong recent price momentum after a strong August, backed by improving earnings expectations.


Delcath Systems to Participate in Upcoming Investor Conferences

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following investor conferences:Wells Fargo Healthcare Conference on Thursday, September 10, 2026...

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

These Two Stocks Hit Fresh 52-Week Highs Today – DCTH Clocks Best Day In Nearly 15 Months

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Delcath Systems raised its 2026 revenue guidance to $104 million to $108 million, up from its previous outlook of at least $100 million.</li><li>As of June 30, 2026, Delcath Systems had $95.9 million in cash and investments and no debt.</li><li>Praxis posted a loss of $2.87 per share, better than Wall Street’s estimates of a loss of $3.66 per share, according to Fiscal.ai.</li></ul>Shares of Delcath Systems (DCTH) and Praxis Precision Medicines (PRAX) hit fresh 52-week highs on Thursday, with DCTH recording its biggest single-day gains in nearly 15 months, after the companies posted better-than-expected second-quarter results.At the time of writing, <a href="https://stocktwits.com/symbol/DCTH">DCTH shares</a> traded 20% higher, having hit an intraday high of $15.62, while <a href="https://stocktwits.com/symbol/PRAX">PRAX stock</a> was up nearly 15%, after hitting an intraday high of $382.54.<h2 class="st-heading-2">DCTH Posts Profit After Two Quarters</h2>Delcath Systems reported better-than-expected second-quarter results, including a return to profitability after posting losses in the past two quarters. Revenue rose to $29.1 million from $24.2 million a year earlier, topping Wall Street estimates of $26.3 million, according to Fiscal.ai.The company posted earnings of $0.07 per share, compared with consensus estimates of a loss of $0.09 per share.Delcath Systems raised its 2026 revenue guidance to $104 million to $108 million, up from its previous outlook of at least $100 million. The company also expects full-year gross margins of 86% to 89%.As of June 30, 2026, Delcath Systems had $95.9 million in cash and investments and no debt.Retail sentiment surrounding DCTH on Stocktwits turned ‘bullish’ from ‘neutral’ over the past 24 hours, amid a 1,250% increase in message volumes. DCTH shares are up more than 53% so far this year.<h2 class="st-heading-2">PRAX’s Funds To Support Operations Till 2028</h2>Praxis Precision Medicines, a pre-revenue biotechnology firm, reported a second-quarter loss that was narrower than Wall Street expected, while ending the quarter with a cash position to support its pipeline through 2028.The company posted a net loss of $83.7 million, or $2.87 per share, better than Wall Street’s estimates of a loss of $3.66 per share, according to Fiscal.ai.Research and development expenses increased to $69.4 million from $63.0 million, primarily due to higher spending on its Solidus program, which is being developed to target rare and prevalent central nervous system (CNS) disorders, and increased personnel costs.As of June 30, 2026, Praxis held $1.4 billion in cash, cash equivalents, and marketable securities, up from $926.1 million at the end of 2025.Retail sentiment surrounding PRAX on Stocktwits flipped to ‘bullish’ from ‘bearish’ over the past 24 hours, amid ‘high’ message volumes. The stock is up more than 28% so far in 2026.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/ast-space-mobile-taps-vodafone-deutsche-telekom-orange-for-europe-expansion-asts-stock-heads-for-best-week-in-over-a-month/cZoB5cfRJJO">AST SpaceMobile Taps Vodafone, Deutsche Telekom, Orange For Europe Expansion – ASTS Stock Heads For Best Week In Over A Month</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

(Photo credit should read INDRANIL MUKHERJEE/AFP via Getty Images)

Delcath Systems announced a return to profitability after posting losses in the past two quarters, while Praxis’ second-quarter loss came in narrower than Wall Street had expected

Praxis Precision Medicines Inc

Very bullish

Cautiously bullish

Cautiously bearish

Very bearish

Stocktwits sentiment on $SPY just hit its lowest level of the year. How are you feeling about the market right now?

Stocktwits

 just hit its lowest level of the year. How are you feeling about the market right now?

Stocktwits Polls

$DCTH The current Estimated Primary Completion date for the Phase 2 MCC with Liver Cancer Dominant trial is December, 2026. Last update was June 1.

Thomas Prindle

$DCTH Beware people…..the street wants to lull you into thinking $16 is the top.  They want your shares so they can get ready for the next run to $25

Chip Davis

$DCTH Remember my comments on Gerrard being conservative. If numbers come below second quarter price will be $14 to $15 range, if about the same as second quarter the price will be $17 to $19 range and if above second quarter  will be $20 to $26 as all the analysts will be all over it and we know we got a winner. Let’s hope for at least the same as second quarter numbers.

Polaris2024

$DCTH I just want to remind you a comment I made after the last earnings call. Gerrard always underestimated their prediction, but last call  for the first time upped his predictions on sales  for the company over what was estimated. This will be big this next quarter and is just a start as this company gains momentum. The base is $16 now and next quarter $20 to $24 are my predictions.

$DCTH Some key findings of independent analysis of CHEMOSAT: "Objective response rate (ORR) was 66.7% and disease control rate (DCR) was 75% per RECIST 1.1."

$DCTH the more they push this down before earnings in 20 days, the more i will buy. I think this is a runner to 25-30 in next 3-6 months

david philip

$DCTH I agree with Wainwrights prediction unless there is a M & A  that happens and if there is strong growth besides the breast cancer approval this estimate would be conservative.

$DCTH currently i think phase 2 initial results will not be before mid 2028 so any big move before 2028 depends on growing revenue, I like the revenue possibilities okay but getting past mid 20s in next 12 months is not likely

Sandi Harris

$DCTH Q3 is done and we are waaaay back on the pace for new site activations. That combined with the possible seasonality because of summerholidays might create a disaster for Delcath Q3...or not :)

Frank Zappa

$DCTH It looks like all of the Delcath ESMO presentations will be on Saturday, October 24.

Feed

News

Sentiment

Earnings

Fundamentals

Info

DCTH Delcath Systems Inc

Fundamentals

Latest DCTH News